Novosanis, a company designs and develops medical devices for a variety of applications, ranging from injection appliances to in vitro diagnostic accessories, has announced that its recently CE-labelled Colli-Pee device which is now ready for the market. With its user-friendly and innovative design, the Colli-Pee offers a non-invasive self-sampling device which could beneficial for healthcare diagnostics.

Colli-Pee efficiently captures first-void urine which allows detection of sexually transmitted infections, including Chlamydia, gonorrhoea next to Human Papilloma Virus which can cause cervical cancer. Colli-Pee is a user-friendly and hygienic device that can be used by both men and women for non-invasive first void urine collection.

Novosanis NV is currently conducting several clinical trials in Flanders, Europa and developing countries on detection of HPV in first void urine. Also, studies on the validations of prostate cancer biomarkers in first void urine are ongoing in Europe.

The Colli-Pee device will be launched by Novosanis at Eurogin 2015 (3-7 Feb 2015 in Sevilla, Spain) and at Innovation for Health (5 Feb 2015, Amsterdam, The Netherlands).

Vanessa Vankerckhoven, chief executive officer, ’Thanks to subsidies from the Flemish Institute for Innovation and Technology (IWT), research and development was enabled which has now led to the first steps of the up-scaled production of the Colli-Pee device. Obtaining the CE label for the Colli-Pee device is an important milestone for Novosanis NV. We exist for almost 2 years now and we are very proud to be able to launch our first device on the market.’

Timothi Van Mulder, Quality Manager: ‘Novosanis NV strives to develop and manufacture highly qualitative devices for healthcare applications. The first years of development and research have led to obtaining the CE label for the Colli-Pee device. Launching Colli-Pee on the market is an excellent reward for the hard work of the entire team.’